22 May 2024 - Availability of Arbysvo is a major step in protecting infants and adults 60 years of age and older and can help to reduce the respiratory syncytial virus disease burden for both families and health care systems.

Pfizer Canada today announces the availability of Abrysvo, its bivalent respiratory syncytial virus vaccine, in Canada. The vaccine was approved in December 2023 by Health Canada for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by the respiratory syncytial virus.

Read Pfizer press release